Monday, November 23, 2009, 3:53pm SGT - The Singapore stock market closes in 1 hour and 7 minutes.
To create a watchlist or portfolio of shares, Register
FINANCE HOME PAGEINVESTINGFINANCE NEWS
    Market:       |  

Omeros Corporation (OMER)

On Nov 21: 7.50 USD  Down 0.20 (2.60%)  
 MORE ON OMER 
Quotes
HereSummary
Charts
News & Info
Company
Analyst Coverage
Ownership
Financials
 Omeros Corporation (NGM:OMER) Delayed quote dataEdit
Last Trade:7.50 USD
Trade Time:Nov 21
Change:Down 0.20 (2.60%)
Prev Close:7.70
Open:7.42
Bid:6.79 x 200
Ask:N/A
1y Target Est:12.25
Day's Range:7.15 - 7.84
52wk Range:5.27 - 9.49
Volume:95,960
Avg Vol (3m):188,147
Market Cap:22.15M
P/E (ttm):N/A
EPS (ttm):-8.68
Div & Yield:N/A (N/A%)
[Chart]
1d  5d  3m 
Use Y! Toolbar to track stocks
 Add OMER to Portfolio   Download Data

 HEADLINES 
•New Star Analyst Rankings for Omeros Corporation
StarMine (Sun 10:19pm)
•Coverage initiated on Omeros by Wedbush Morgan
Briefing.com (Sat, Nov 21)
•OMEROS CORP Files SEC form 8-K, Results of Operations and Financial Condition
EDGAR Online (Fri, Nov 20)
•Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights
PR Newswire (Fri, Nov 20)
•Q3 2009 OMEROS CORP Earnings Release - After Market Close
CCBN (Thu, Nov 19)
•Omeros Corporation to Host Third Quarter 2009 Financial Results Conference Call on November 19
PR Newswire (Fri, Nov 13)
•OMEROS CORP Files SEC form 8-K, Entry into a Material Definitive Agreement
EDGAR Online (Thu, Nov 12)
•CEO Interview: Winston Pharmaceuticals, Inc. - Dr. Joel E. Bernstein
Wall Street Transcript (Tue, Nov 3)
•Hyatt Hotels to Test the IPO Waters
at The Wall Street Journal Online (Mon, Nov 2)
•Road to Market Becomes More Difficult in the U.S.
at The Wall Street Journal Online (Mon, Nov 2)
More Headlines for OMER...
 ANALYST 
EPS Est (next year) (Dec-09) :-1.44
EPS Est (in 2 years) (Dec-10) :-1.47
Avg Rec (current)*:1.5
PEG Ratio:N/A
* (Strong Buy) 1.0 - 5.0 (Strong Sell)
Analyst Opinion - Estimates

 BUSINESS SUMMARY 
Omeros Corporation, a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing products on inflammation and disorders of the central nervous system.

Full Company Profile



Add to My Portfolio Add to Portfolio    Email to a Friend Email to a Friend
Get Summary for Another Symbol:
Search by Company
•Latest News•Singapore Indices